Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 19/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8029768 | 0.82 | ADORA2A (0.69) | ADORA2AADORA1ALDH1A1MAPT | |
| SCHEMBL8029365 | 0.78 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL8037347 | 0.74 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL8069784 | 0.74 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL4102329 | 0.73 | ALDH1A1 (0.59) | ADORA2AADORA1ALDH1A1MAPT | |
| SCHEMBL1378743 | 0.72 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL4106909 | 0.71 | ALDH1A1 (0.57) | ADORA2AADORA1ALDH1A1MAPT | |
| SCHEMBL12034929 | 0.71 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL8072372 | 0.71 | ADORA2A (0.73) | ADORA2AADORA1 | |
| SCHEMBL8032770 | 0.70 | ADORA2A (0.82) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017614-B2 | Arylindenopyrimidines compound and use as an adenosine A2a receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017614-B2 | Arylindenopyrimidines compound and use as an adenosine A2a receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017614-B2 | Arylindenopyrimidines compound and use as an adenosine A2a receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-13 | — | — | US | disclosed |
| EP-2217575-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009055308-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055308-A1 | ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111827-A1 | ARYLINDENOPYRIMIDINES COMPOUND AND USE AS AN ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111827-A1 | ARYLINDENOPYRIMIDINES COMPOUND AND USE AS AN ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111827-A1 | ARYLINDENOPYRIMIDINES COMPOUND AND USE AS AN ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111827-A1 | ARYLINDENOPYRIMIDINES COMPOUND AND USE AS AN ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 4/4885ALDH1A1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.